Eloxx director exercises RSUs, receives stock options

Eloxx Pharmaceuticals director Alan Edmund Walts reported equity compensation activity, not open‑market trading.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Eloxx Pharmaceuticals director Alan Edmund Walts reported equity compensation activity, not open‑market trading. On January 24, 2026, he exercised 1,875 restricted stock units, receiving an equal number of common shares at a stated price of $0.00 per share, bringing his directly held common stock to 15,567 shares.

A prior grant on September 19, 2025 awarded him a stock option for 395,680 shares of common stock at an exercise price of $0.15 per share, expiring on September 19, 2035. The option vests over 36 months, and the RSUs vested 50% after one year with the balance in two annual installments.

Insider Trade Summary

1,875 shares exercised/converted

Exercise 3 txns

Insider Walts Alan Edmund

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,875	$0.00	$0.00
Exercise	Common Stock	1,875	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	395,680	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 395,680 contracts (Direct); Restricted Stock Units — 1,875 contracts (Direct); Common Stock — 15,567 shares (Direct)

Footnotes (3)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2. The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
F3. The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter.

Key Figures

RSUs exercised: 1,875 shares Common shares held: 15,567 shares Stock option grant size: 395,680 shares +4 more

7 metrics

RSUs exercised 1,875 shares Converted to common stock on January 24, 2026 at $0.00

Common shares held 15,567 shares Direct ownership after January 24, 2026 RSU conversion

Stock option grant size 395,680 shares Option granted September 19, 2025 on Eloxx common stock

Stock option exercise price $0.15 per share Conversion or exercise price for 395,680-share option

Option expiration September 19, 2035 Expiration date of 395,680-share stock option

RSU vesting schedule 50% then two annual installments RSUs tied to January 24, 2024 grant anniversary

Option vesting start 1/36 on October 31, 2025 Remaining 35/36 vest in equal monthly increments

Key Terms

Restricted Stock Units, stock option, exercise price, vested, +1 more

5 terms

Restricted Stock Units financial

"The RSUs vested as to 50% on the first anniversary of January 24, 2024"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock option financial

"The stock option vested as to 1/36 on October 31, 2025"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "0.1500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"The RSUs vested as to 50% on the first anniversary of January 24, 2024"

common stock financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eloxx (ELOX) director Alan Edmund Walts report in this Form 4?

Alan Edmund Walts reported equity compensation activity, not open‑market trading. He exercised 1,875 restricted stock units into common shares and holds 15,567 common shares afterward, alongside a previously granted stock option covering 395,680 shares of Eloxx common stock.

How many Eloxx common shares does Alan Edmund Walts hold after these transactions?

After exercising restricted stock units, Walts directly holds 15,567 shares of Eloxx common stock. These shares result from converting 1,875 RSUs on January 24, 2026, at a stated price of $0.00 per share, as part of his equity compensation package.

What are the key terms of Alan Edmund Walts’ Eloxx stock option grant?

Walts received a stock option for 395,680 Eloxx common shares at a $0.15 exercise price. The option was granted September 19, 2025, expires September 19, 2035, and vests monthly over 36 months after an initial vesting of 1/36 on October 31, 2025.

How do Alan Edmund Walts’ Eloxx RSUs vest according to the filing?

The RSUs vested 50% on the first anniversary of January 24, 2024, with the remaining half vesting in two equal annual installments. Each restricted stock unit represents a contingent right to receive one Eloxx common share when the specified vesting conditions are satisfied.

Did Alan Edmund Walts buy or sell Eloxx (ELOX) shares on the open market?

The Form 4 does not show any open‑market buy or sell transactions. It reports an RSU conversion into 1,875 common shares at $0.00 per share and a prior stock option grant, both classified as equity compensation rather than discretionary market trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/08/2026 - 04:44 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walts Alan Edmund

(Last)

(First)

(Middle)

C/O ELOXX PHARMACEUTICALS, INC.

P.O. BOX 274

(Street)

ARLINGTON

MASSACHUSETTS

02476

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/24/2026		M		1,875	A	⁽¹⁾	15,567	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.15	09/19/2025		A		395,680		⁽²⁾	09/19/2035	Common Stock	395,680	$0	395,680	D
Restricted Stock Units	⁽¹⁾	01/24/2026		M			1,875	⁽³⁾	⁽³⁾	Common Stock	1,875	$0	1,875	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

3. The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter.

	/s/ Sumit Aggarwal, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR